5/16/2013

Label changes, including lower doses for sleep treatments with zolpidem, a drug that affects the mental alertness of patients even a day after its intake, were approved by the FDA. Driving and other activities that require complete mental alertness the following day should be avoided by patients who receive zolpidem extended-release medications, the agency said. The approval covered label changes for Sanofi's Ambien and Ambien CR, as well as Meda's Edluar.

Full Story:
Reuters

Related Summaries